Extreme outlier analysis identifies occult mitogen- activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Cystadenocarcinoma, Serous
  • Drug Resistance, Neoplasm
  • MAP Kinase Kinase 1
  • Mutation
  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms

abstract

  • Alterations affecting the mitogen-activated protein kinase pathway are present in the majority of patients with LGS ovarian cancer. Next-generation sequencing analysis revealed deletions and fusions that are not detected by older sequencing approaches. These findings, coupled with the observation that a subset of patients with recurrent LGS ovarian cancer experienced dramatic and durable responses to MEK inhibitor therapy, support additional clinical studies of MEK inhibitors in this disease.

publication date

  • December 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4669594

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.62.4726

PubMed ID

  • 26324360

Additional Document Info

start page

  • 4099

end page

  • 105

volume

  • 33

number

  • 34